XY028-140

N/A

Report date: 2022/12/29 15:53:19
NME

Base Information

Drug NameXY028-140
Drug Alias NameXY028-140
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionCyclin-dependent kinase 4 inhibitorsCyclin-dependent kinase 6 inhibitorsProteolysis
TargetsCyclin-dependent kinase 4Cyclin-dependent kinase 6
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIcahn School Of Medicine At Mount Sinai
China Registration ClassN/A

Develop Information

Active CompaniesIcahn School Of Medicine At Mount Sinai
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A